Hematopoiesis News Volume 4.29 | Jul 30 2013

    0
    21
    Hematopoiesis News 4.29 July 30, 2013

    Hematopoiesis News

    In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs

    TOP STORY
    Hif-2α Is Not Essential for Cell-Autonomous Hematopoietic Stem Cell Maintenance
    Researchers demonstrated that constitutive or inducible hematopoiesis-specific Hif-2α deletion does not affect hematopoietic stem cell (HSC) numbers and steady-state hematopoiesis. Furthermore, using serial transplantations and 5-FU treatment they demonstrated that HSCs do not require Hif-2α to self-renew and recover following hematopoietic injury. [Blood] Abstract

    Take the if out of diff. Reduce variability when Differentiating to Hematopoietic Cells

    PUBLICATIONS ( Ranked by impact factor of the journal)
    LABORATORY RESEARCH

    Staphylococcus aureus Recognition by Hematopoietic Stem and Progenitor Cells via TLR2/MyD88/PGE2 Stimulates Granulopoiesis in Wounds
    Previously, the authors reported that hematopoietic stem and progenitor cells (HSPCs) recruited to S. aureus-infected skin wounds in mice, undergo granulopoiesis, while others have demonstrated their differentiation in vitro after TLR2/MyD88 stimulation. In this study, they examined this pathway in HSPC trafficking and granulopoiesis within S. aureus-infected wounds. [Blood] Abstract

    The Combined Influence of Substrate Elasticity and Surface-Grafted Molecules on the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells
    Because little is known about the effects of the physical microenvironment on hematopoietic stem and progenitor cell (HSPC) expansion, the authors investigated the ex vivo expansion of HSPCs cultured on biomaterials with different elasticities and grafted with different nanosegments. [Biomaterials] Abstract

    Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene Therapy Corrects a Neuronopathic Lysosomal Disease
    To improve brain expression via monocyte/microglial specificity, lentiviral vectors (LVs) expressing enhanced green fluorescent protein (eGFP) under ubiquitous phosphoglycerate kinase (PGK) or myeloid-specific promoters were compared in transplanted hematopoietic stem cells. LV-CD11b-GFP gave significantly higher monocyte/B-cell eGFP expression than LV-PGK-GFP or LV-CD18-GFP after six months. [Mol Ther]
    Full Article
    | Press Release

    No Impact of Lentiviral Transduction on Hematopoietic Stem/Progenitor Cell Telomere Length or Gene Expression in the Rhesus Macaque Model
    Scientists utilized two techniques to examine whether lentivirally-transduced hematopoietic stem and progenitor cells from eight rhesus macaques transplanted 1-13.5 years previously are perturbed at a population level, comparing telomere length as a measure of replicative history and gene expression profile of vector positive versus vector negative cells. [Mol Ther] Abstract

    Isolation, Characterization and Transplantation of Bone Marrow Derived Cell Component with Hematopoietic Stem Cell Niche Properties
    Investigators isolated cell complexes based on size fractionation from mouse bone marrow (BM), characterized the derived cells, and transplanted them to irradiated mice. These cell complexes were the origin of both BM mesenchymal stem cells and various hematopoietic lineages when kept in appropriate culture conditions. [Stem Cell Dev] Abstract

    Human Proangiogenic Circulating Hematopoietic Stem and Progenitor Cells Promote Tumor Growth in an Orthotopic Melanoma Xenograft Model
    The authors previously identified a distinct population of human circulating hematopoietic stem and progenitor cells (CHSPCs) in the peripheral blood (PB) and bone marrow, and that their frequency in the PB can correlate with disease state. The proangiogenic subset (pCHSPC) play a role in regulating tumor progression, for they previously demonstrated a statistically significant increase in C32 melanoma growth in NOD.Cg-Prkdc scid injected with human pCHSPCs. In this paper, they provide further evidence that pCHSPCs possess proangiogenic properties. [Angiogenesis] Abstract

    Do Pluripotent Stem Cells Exist in Adult Mice as Very Small Embryonic Stem Cells?
    Researchers showed that they could not find very small embryonic stem cells in mouse bone marrow with any of the reported stem cell potentials, specifically for hematopoiesis. [Stem Cell Reports]
    Full Article | Press Release

    CLINICAL RESEARCH

    The Value of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation in Prognostically Favorable Acute Myeloid Leukemia with Double Mutant CEBPA
    Among 2983 patients analyzed for CEBPA mutational status treated on four HOVON/SAKK and three AMLSG protocols; 124 had acute myeloid leukemia with double mutant CEBPA and achieved first complete remission. Evaluation of the clinical impact of allogeneic and autologous hematopoietic stem cell transplantation versus chemotherapy was performed by addressing time dependency in the statistical analyses. [Blood] Abstract

    First-Line Allogeneic Hematopoietic Stem Cell Transplantation of HLA-Matched Sibling Donors Compared with First-Line Ciclosporin and/or Antithymocyte or Antilymphocyte Globulin for Acquired Severe Aplastic Anemia
    The authors evaluated the effectiveness and adverse events of first-line allogeneic hematopoietic stem cell transplantation of human leukocyte antigen (HLA)-matched sibling donors compared to first-line immunosuppressive therapy including ciclosporin and/or antithymocyte or antilymphocyte globulin in patients with acquired severe aplastic anemia. [Cochrane Database Syst Rev] Abstract

    Technical Bulletin: Assays For Cord Blood

    REVIEWS
    Hormonal Control of Stem Cell Systems
    The authors examined how hormones affect stem cell biology in four different organs: the ovary, intestine, hematopoietic system, and mammary gland. [Annu Rev Cell Dev Biol] Abstract

    From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

    INDUSTRY NEWS
    Roche’s Obinutuzumab Delayed Disease Progression Longer than MabThera/Rituxan in People with One of the Most Common Forms of Blood Cancer
    Roche announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival) compared to MabThera/Rituxan plus chlorambucil. [F. Hoffmann-La Roche Ltd.] Press Release

    Quest Diagnostics Sells Ibrutinib Royalty Rights to Royalty Pharma For $485 Million in Cash
    Quest Diagnostics Incorporated announced that it has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma for $485 million in cash. As part of its acquisition of Celera in 2011, Quest Diagnostics gained rights to royalties on ibrutinib, an experimental cancer therapy currently in Phase III development by Pharmacyclics and Johnson & Johnson, through its Janssen Biotech subsidiary. [Quest Diagnostics Incorporated] Press Release

    From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS
    NEW Hematology Society of Australia & New Zealand Annual Scientific Meeting 2013
    October 20-23, 2013
    Gold Coast, Australia

    NEW IBC’s 3rd Annual Cell Therapy Bioprocessing
    October 21-23, 2013
    Bethesda, United States

    NEW IBC’s Biopharmaceutical Development & Production (BDP) Week: Methods & Molecules
    March 24-27, 2014
    San Diego, United States

    Visit our events page to see a complete list of events in the hematopoiesis research community.

    JOB OPPORTUNITIES
    NEW Postdoctoral Researcher – Mechanisms Regulating Hematopoietic Stem Cell (Albert Einstein College of Medicine)

    Postdoctoral Position – Computational Analysis of Genome-Wide Data of Normal and Malignant Blood Cells (University of Copenhagen, Department of Biomedical Sciences)

    Postdoctoral Position – Stem Cell Biology (St. Jude Children’s Research Hospital)

    Postdoctoral Fellow – Cancer Stem Cell Biology (McGill University)

    Postdoctoral Position – Hematopoietic Differentiation of Pluripotent Stem Cells (Center for Physiology and Pathophysiology, University of Cologne)

    Research Associate (Assistant Professor) – Pediatric Hematology/Oncology (The University of Chicago)

    Postdoctoral Research Fellow – Hematology/Pharmacology (Thomas Jefferson University, Cardeza Foundation for Hematologic Research)

    Postdoctoral Positions – Stem Cell Biology and Epigenetics (University of Wisconsin-Madison)

    Director of Cell Processing Facility (S L Collins Associates, Inc.)

    Postdoctoral Researcher – Hematopoietic Stem Cells (Albert Einstein College of Medicine)

    Studentship – Novel Mechanisms in Blood Cancers Drug-Resistance (University of East Anglia)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Hematopoiesis News: Archives | Events | Contact Us